Fig. 2From: Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studiesChronic migraine: proportions of patients with maintenance of ≥ 50% response for 3 consecutive months. Abbreviations: OR = odds ratio. *** = p < 0.001Back to article page